Margaret Olinger - Mar 16, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Chief Commercial Officer
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol: AMLX
Transactions as of: Mar 16, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/20/2023, 08:27 PM
Previous filing: Jan 10, 2023
Next filing: May 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Award	$0	+18.3K	+8.55%	$0.00	233K	Mar 16, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (right to buy)	Award	$0	+82.5K		$0.00	82.5K	Mar 16, 2023	Common Stock	82.5K	$32.08	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F2	1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.